| David Gerard Baker, MD | |
|
1001 S George St, York, PA 17403-3676 | |
| (717) 812-7687 | |
| Not Available |
| Full Name | David Gerard Baker |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 42 Years |
| Location | 1001 S George St, York, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144212622 | NPI | - | NPPES |
| 001093784 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD035607E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
› Verified 2 days ago
| Entity Name | Anesthesia Associates Of York Pa Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205812260 PECOS PAC ID: 2769394949 Enrollment ID: O20031105000332 |
News Archive
Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
› Verified 2 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Gerard Baker, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 812-7687 | David Gerard Baker, MD 1001 S George St, York, PA 17403-3676 Ph: (717) 812-7687 |
News Archive
Stem cells offer great potential in biomedical engineering due to their pluripotency, which is the ability to multiply indefinitely and also to differentiate and develop into any kind of the hundreds of different cells and bodily tissues. But the precise complexity of how stem cell development is regulated throughout states of cellular change has been difficult to pinpoint until now.
The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Boston Scientific Corporation today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away Lead Delivery System for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.
› Verified 2 days ago
Van D Adams, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 325 S Belmont St, York, PA 17403 Phone: 717-843-8623 | |
Surendra Davuluri, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1001 S George St, York, PA 17403 Phone: 717-851-2345 | |
Sudhakar Reddy Yennam, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1001 S George St, York, PA 17403 Phone: 717-812-7687 | |
Dr. Michael Allen Klein, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1855 Powder Mill Rd, York, PA 17402 Phone: 717-848-4800 Fax: 717-741-9539 | |
Barrett E Giffel, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 25 Monument Rd Ste 270, York, PA 17403 Phone: 717-741-8250 Fax: 717-741-8289 | |
Daniel Derewitz, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1001 S George St, York, PA 17403 Phone: 717-851-2345 | |
Claudia Deitrich, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1001 S George St, York, PA 17403 Phone: 717-851-2345 |